Kestra Private Wealth Services LLC Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Kestra Private Wealth Services LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 12,657 shares of the medical research company's stock after acquiring an additional 743 shares during the quarter. Kestra Private Wealth Services LLC's holdings in Thermo Fisher Scientific were worth $6,298,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Auxano Advisors LLC grew its holdings in Thermo Fisher Scientific by 9.6% in the 1st quarter. Auxano Advisors LLC now owns 538 shares of the medical research company's stock valued at $268,000 after buying an additional 47 shares in the last quarter. Private Advisor Group LLC boosted its holdings in Thermo Fisher Scientific by 5.0% during the 1st quarter. Private Advisor Group LLC now owns 22,750 shares of the medical research company's stock valued at $11,320,000 after acquiring an additional 1,087 shares during the period. Pictet Asset Management Holding SA boosted its holdings in Thermo Fisher Scientific by 7.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock valued at $1,432,816,000 after acquiring an additional 193,378 shares during the period. Creekmur Asset Management LLC raised its position in Thermo Fisher Scientific by 1,678.3% in the 1st quarter. Creekmur Asset Management LLC now owns 409 shares of the medical research company's stock valued at $204,000 after purchasing an additional 386 shares in the last quarter. Finally, Markel Group Inc. raised its position in shares of Thermo Fisher Scientific by 9.5% during the 1st quarter. Markel Group Inc. now owns 45,000 shares of the medical research company's stock worth $22,392,000 after acquiring an additional 3,900 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 2.3%

Shares of Thermo Fisher Scientific stock opened at $415.29 on Friday. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The business's 50 day simple moving average is $410.38 and its 200-day simple moving average is $472.67. The stock has a market capitalization of $156.77 billion, a price-to-earnings ratio of 24.36, a PEG ratio of 2.21 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the company posted $5.11 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Analysts Set New Price Targets

Several research analysts have weighed in on TMO shares. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. UBS Group cut Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $500.00 to $460.00 in a report on Tuesday, July 8th. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Finally, Royal Bank Of Canada reduced their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $599.30.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.